- Home
- WTI vs ALDX Comparison
WTI vs ALDX Comparison
Compare WTI & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WTI | ALDX |
|---|---|---|
| Founded | 1983 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 260.4M | 293.0M |
| IPO Year | 2005 | 2014 |
Fundamental Metrics
Financial Performance| Metric | WTI | ALDX |
|---|---|---|
| Price | $1.63 | $5.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.50 |
| AVG Volume (30 Days) | 1.3M | ★ 1.6M |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | ★ 2.45% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $500,094,000.00 | N/A |
| Revenue This Year | $0.31 | N/A |
| Revenue Next Year | N/A | $36.25 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.09 | $1.14 |
| 52 Week High | $2.59 | $7.20 |
Technical Indicators
Market Signals| Indicator | WTI | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 37.92 | 53.77 |
| Support Level | $1.66 | $4.98 |
| Resistance Level | $1.80 | $5.75 |
| Average True Range (ATR) | 0.07 | 0.47 |
| MACD | 0.00 | 0.07 |
| Stochastic Oscillator | 15.37 | 75.07 |
Price Performance
Historical ComparisonAbout WTI W&T Offshore Inc.
W&T Offshore Inc is an oil and gas exploration and production company. The company's exploration operations are focused in the Gulf of Mexico, where it drills for oil and gas. The company engages in both deepwater drilling and shallow-water shelf drilling. W&T Offshore extracts crude oil, natural gas, and natural gas liquids, which are then sold directly at the wellhead. Overall, crude oil accounts for the majority of company's revenue, with natural gas accounting for a much smaller portion.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.